RESOURCEPATH LLC
Sterling, VA · Medtech · Private
DICER-Dx, a biomarker assay panel detecting DICER1 hotspot mutations in tumor samples to identify DICER1 syndrome cancers and assess chemotherapy response
pepperpath.net →- Grants
- $3.8M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $750K
- 2 awards · Health and Human S
- #346 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · DICER-Dx: The First Liquid Biopsy for Early Detection and Monitoring of DICER1 Syndrome Pediatric Cancers | $299,514 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · DICER-Dx: The First Liquid Biopsy for Early Detection and Monitoring of DICER1 Syndrome Pediatric Cancers | $299,514 | |
| Federal grant | Department of Health and Human Services · Phase II · DICER-Dx: The First Liquid Biopsy for Early Detection and Monitoring of DICER1 Syndrome Pediatric Cancers | $749,883 | |
| Federal grant | Department of Health and Human Services · Phase II · DICER-Dx: The First Liquid Biopsy for Early Detection and Monitoring of DICER1 Syndrome Pediatric Cancers | $1,496,887 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and Validation of Liquid Biopsy ddPCR and Next Generation Sequencing Assays for Diffuse Midline Glioma, K27M Variant | $224,679 | |
| Federal grant | Department of Health and Human Services · Phase II · DICER-Dx: The First Liquid Biopsy for Early Detection and Monitoring of DICER1 Syndrome Pediatric Cancers | $747,004 | |
| Federal contract· 1 of 2 same day | Department of Health and Human Services · Diagnostics Pre-clinical Services Program | $746,197 | |
| Federal contract· 2 of 2 same day | Department of Health and Human Services · Diagnostics Pre-clinical Services Program - Idiq - Resourcepath | $3,500 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 343 | GRADIENT HEALTH, INC. | $766K | $7.9M |
| 344 | SIMPHOTEK, INC. | $755K | $1.1M |
| 345 | NanoEngineering Corporation | $753K | $1.4M |
| 346 | RESOURCEPATH LLC | $750K | — |
| 347 | CHARLOT BIOSCIENCES INC | $750K | — |
| 348 | VAXESS TECHNOLOGIES INC | $749K | — |
| 349 | LifeCanvas Technologies Inc. | $738K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.